Necip, KaraOltulu, RefikLevent, DoganOsman, Gundogan Ali2024-02-232024-02-2320210277-37401536-4798https://doi.org/10.1097/ICO.0000000000002524https://hdl.handle.net/20.500.12452/13464Purpose: To evaluate the outcomes of Descemet membrane endothelial keratoplasty (DMEK) in patients with toxic anterior segment syndrome (TASS). Methods: Thirteen eyes of 13 patients who underwent DMEK for endothelial decompensation secondary to TASS were retrospectively reviewed. A comprehensive ocular examination including best-corrected visual acuity (BCVA), slitlamp biomicroscopy, intraocular pressure measurement, fundus evaluation, and measurement of central corneal thickness were performed in all patients at preoperatively and postoperatively. Results: There were 8 men and 5 women, with an average age of 56 +/- 19 years. The mean follow-up was 8.7 +/- 3.5 months. The time interval between the onset of TASS and DMEK was 4.9.+/- 6.6 months (range, 1.5-26 months). Twelve of 13 grafts were clear at last visit. The mean preoperative BCVA was 20/666 (range, hand motion to 20/200), and the mean BCVA was 20/36 (range, hand motion to 20/20) at the postoperative last visit (P = 0.003). The decrease in mean pachymetry from preoperative (768 +/- 69 mu m) to postoperative last visit (523 +/- 71 mu m) was statistically significant (P < 0.001). Conclusions: DMEK seems to be a safe and an effective treatment option in eyes with TASS-related endothelial decompensation.eninfo:eu-repo/semantics/closedAccessToxic Anterior Segment SyndromeCorneal EdemaEndothelial KeratoplastyArticle40810071010330090922-s2.0-85111789202Q1WOS:000711685000012Q210.1097/ICO.0000000000002524